ANDA 90291, held by Chartwell Rx. Cefepime Hydrochloride.
As of Nov 16, 2026, ANDA 90291 (Cefepime Hydrochloride), held by Chartwell Rx, was first approved by FDA on Dec 21, 2010, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 21, 2010 | Original application | Approved | None posted |
| Cefepime HydrochlorideEQ 500MG BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Discontinued |
| Cefepime HydrochlorideEQ 1GM BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Discontinued |
| Cefepime HydrochlorideEQ 2GM BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Discontinued |
| Aug 15, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 21, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters